Rhinovirus/Enterovirus Encephalitis: Evaluation and Treatment
No specific antiviral treatment is recommended for enterovirus encephalitis; however, in severe cases—particularly in immunocompromised patients—intravenous immunoglobulin (IVIG) should be strongly considered, with pleconaril or investigational antivirals as additional options if available. 1
Immediate Evaluation and Stabilization
Critical Initial Steps
Patients with suspected enterovirus encephalitis require:
- Urgent neurological specialist consultation within 24 hours 1
- ICU assessment if declining consciousness for airway protection, ventilatory support, management of raised intracranial pressure, and correction of electrolyte imbalances 1
- Immediate neuroimaging (MRI preferred over CT) and EEG access, with transfer to neuroscience unit if needed 1
Diagnostic Workup
Lumbar puncture with CSF analysis is essential 1, 2:
- CSF PCR for enterovirus (results should be available within 24-48 hours) 1
- CSF protein, glucose, and cellular analysis 2, 3
- If CSF PCR is negative but clinical suspicion remains high, consider testing alternative specimens (throat swabs, stool, blood) as enteroviruses may be detected at other sites 4
Important caveat: While awaiting diagnostic confirmation, if there is strong clinical suspicion of viral encephalitis and the patient is deteriorating, empiric acyclovir (10 mg/kg IV every 8 hours) should be started within 6 hours to cover HSV encephalitis, which is treatable and has high mortality if untreated 1, 5. Acyclovir has no activity against enteroviruses but must be given empirically until HSV is excluded.
Treatment Algorithm
For Immunocompetent Patients
Supportive care is the mainstay 1:
- Most enterovirus encephalitis cases are self-limiting
- Close monitoring in neurological ward, HDU, or ICU setting
- Seizure management, ICP control, and symptomatic treatment
For Severe Disease or Immunocompromised Patients
IVIG is the primary therapeutic intervention to consider 1, 6:
- Evidence from case series suggests survival advantage in immunosuppressed patients 6
- Particularly important in patients with hypogammaglobulinemia (even moderate IgG reduction) 6
- High-dose IVIG has shown clinical and microbiological improvement 7
- Rarely associated with severe adverse events 6
Investigational antivirals may be considered 1:
- Pleconaril: Broad activity against enteroviruses at low concentrations; reduced symptoms in aseptic meningitis trials by ~2 days but no trials in encephalitis; not easily available 1, 3
- Pocapavir: Used in recent case reports with some success 4
- Favipiravir + fluoxetine combination: Novel regimen showing promise in severe cases, particularly in immunocompromised hosts 7
High-Risk Populations Requiring Aggressive Treatment
Immunocompromised patients are at dramatically higher risk 4, 6:
- B-cell depleting therapies (rituximab, ocrelizumab)
- Agammaglobulinemia or hypogammaglobulinemia
- Post-transplant or chemotherapy patients
- SCID or other primary immunodeficiencies
In these patients, early IVIG initiation is critical as they face higher mortality and risk of chronic infection 4, 6.
Key Clinical Pitfalls
Do not withhold empiric acyclovir while waiting for enterovirus confirmation—HSV must be covered initially 1
Do not assume mild disease in immunocompromised patients—enterovirus can cause devastating CNS involvement with high mortality (12/42 deaths in anti-CD20 case series) 4
Do not rely solely on CSF PCR—if negative but suspicion high, test alternative sites (throat, stool, blood) 4
Monitor for deterioration requiring transfer—if diagnosis not rapidly established or patient fails to improve, transfer to neurological unit within 24 hours 1
Evidence Quality and Nuances
The guideline recommendations are based on Level C, Grade III evidence 1—meaning expert opinion and case series rather than randomized trials. This reflects the rarity of enterovirus encephalitis and lack of controlled studies. The British guidelines (2012) remain the most authoritative source, consistently stating no specific treatment is recommended for routine cases but acknowledging IVIG and pleconaril for severe disease.
Recent case reports (2021-2026) suggest IVIG may confer survival benefit in immunosuppressed patients 6, and novel combinations like favipiravir-fluoxetine show promise 7, but these remain investigational.
Corticosteroids are not recommended for enterovirus encephalitis, unlike VZV encephalitis where they may have a role 1, 2, 3.